| Active substance | sacituzumab govitecan |
| Holder | Gilead |
| Status | closed |
| Indication | treatment in monotherapy of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease and with no adequate treatment options |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 21/12/2022 |